|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Homologous recombination deficiency and ovarian cancer 显示文摘 | Ledermann J A Drew Y Kristeleit R S | 2016 | Eur J Cancer2016，60，： | 1 |
| 2 | Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer(MRC FOCUS):a randomised controlled trial显示文摘 | Seymour M T Maughan T S Ledermann J A | 2007 | Lancet2007，370，9582： | 1 |
| 3 | Proliferation,but not growth, blocked by conditional deletion of 40S ribosomal protein S6显示文摘 | Volarevic S Stewart MJ Ledermann B | 2000 | Science2000，288，5473： | 1 |
| 4 | Estimating,testing and comparing specific effects in structural equation models:the phantom model approach显示文摘 | Macho S Ledermann T | 2011 | Psychol Methods2011，16，1： | 1 |
| 5 | Evaluation of quality of life by young adult survivors of severe chronic kidney disease in infancy显示文摘 | MEKAHLI D LEDERMANN S GULLETT A | 2014 | Pediatr Nephrol2014，29，8： | 1 |
| 6 | Pharmacological inhibition of integrin αvβ3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis显示文摘 | Eleonora Patsenker Yury Popov Felix Stickel Vreni Schneider Monika Ledermann Hans S?gesser Gerald Niedobitek Simon L. Goodman Detlef Schuppan | 2009 | Hepatology2009，，5： | 1 |
| 7 | Choice of fluids for resuscitation in children with severe infection and shock: systematic review显示文摘 | Akech S Ledermann H Maitland K | 2010 | BMJ2010，341，： | 1 |
| 8 | Applying a systems model of training to a patient with coronary artery disease显示文摘 | LE BRIS S LEDERMANN B CANDAU R | 2004 | Med Sci Sports Exe2004，36，6： | 1 |
| 9 | Proliferation,but not growth,blocked by conditional deletion of 40S ribosomal protein S6显示文摘 | Volarevic S Stewart MJ Ledermann B | 2000 | Science2000，288，5473： | 1 |
| 10 | Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial显示文摘 | David J Kerr Colin S McArdle Jonathan Ledermann Irving Taylor David J Sherlock Peter M Schlag John Buckels David Mayer Dionne Cain Richard J Stephens | 2003 | The Lancet2003，，9355： | 1 |
| 11 | Relationship between hepatic mitochondrial functions in vivo and in vitro in rats with carbon tetrachloride-induced liver cirrhosis显示文摘 | Krdhenbiihl L Ledermann M Krahenbiihl S | 2000 | Hepatology2000，33，： | 1 |
| 12 | Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer 显示文摘 | Ledermann JA Hackshaw A Kaye S | 2011 | J Clin Oncol2011，29，28： | 1 |
| 13 | Maintenance therapy in ovarian cancer显示文摘 | KhaIique S Hook JM Ledermann ]A | 2014 | Curr Opin Oncol2014，26，5： | 1 |
| 14 | Applying a systems model of training to a patient with coronary artery disease显示文摘 | Le Bris S Ledermann B Candau R | 2004 | Med Sci Sports Exerc2004，36，6： | 1 |
| 15 | Proliferation, but not growth, blocked by conditional delection of 40S ribosomal protein S6显示文摘 | Volarevic S Stewart MJ Ledermann B | 2000 | Science2000，288，5473： | 1 |
| 16 | Proliferation, but not growth, blocked by conditional deletion of 40S ribosomal protein S6显示文摘 | VOLAREVIC S STEWART M J LEDERMANN ]3 | 2000 | Science2000，288，： | 1 |
| 17 | Dif-ferent strategies of sequential and combination chemotherapy forpatients with poor prognosis advanced colorectal cancer ( MRC FO-CUS) :a randomised controlled trial 显示文摘 | SEYMOUR M T MAUGHAN T S LEDERMANN J A | 2007 | Lancet2007，370，9582： | 1 |
| 18 | Chronic hemodialysis in infants and children under 2 year of age显示文摘 | SHROFF R WRIGHT E LEDERMANN S | 2003 | Pe-diatr Nephrul2003，18，： | 1 |
| 19 | How should we manage patients with 'platinum-sensitive' recurrent ovarian cancer显示文摘 | Jonathan A Ledermann Wheeler S | 2004 | Cancer Investigation2004，22，2： | 1 |
| 20 | 奥拉帕利维持治疗BRCA 1/2突变铂敏感复发性卵巢癌患者(SOLO2/ENGOT-Ov21):一项双盲随机对照Ⅲ期试验的最终分析显示文摘背景既往发表的SOLO2/ENGOT-Ov21试验的第一部分研究结果表明,作为BRCA1或BRCA2(BRCA1/2)突变铂敏感型的高级别浆液性或子宫内膜样卵巢癌复发患者使用奥拉帕利可延长无进展生存期。因此,本研究的最终分析目的是研究奥拉帕利对这类患者总生存期的影响。方法本研究是一项在16个国家123个医疗中心进行的双盲、随机、安慰剂对照、Ⅲ期临床试验。纳入标准包括:年龄≥18岁;ECOG体能状态评分基线水平为0~1分;组织学检查确诊为复发性、高级别浆液性或高级别子宫内膜样卵巢癌,包括原发性腹膜癌或输卵管癌;以及既往接受过2种或2种以上铂类药物的治疗方案。入选患者按2∶1分配到奥拉帕利组(150 mg片剂,每日2次口服,共300 mg)或安慰剂组;根据既往化疗后是否缓解以及无铂治疗间隔时长进行分层;受试者、治疗提供者和数据分析人员在治疗分配时均设盲。主要终点是既往已报道过的无进展生存期;总生存期作为重要的次要终点之一,在所有随机分配的患者中进行分析;安全性评估在至少接受过1次给药的所有患者中进行。结果2013年9月3日—2014年11月21日,共295例患者参与了试验并被随机分到奥拉帕利组(196例,66%)或安慰剂组(99例,34%)治疗。奥拉帕利组患者中位随访时间为65.7个月(IQR:63.6~69.3),安慰剂组为64.5个月(IQR:63.4~68.7)。奥拉帕利组中位总生存期为51.7个月(95%CI:41.5~59.1),安慰剂组为38.8个月(95%CI:31.4~48.6)(HR=0.74,95%CI:0.54~1.00,P=0.054)。安慰剂组38%接受PARP抑制剂治疗的患者未作调整。治疗引发的最常见的Ⅲ级以上不良事件为贫血,奥拉帕利组发生率为21%(41/195),安慰剂组为2%(2/99)。 | Andrés Poveda Anne Floquet Jonathan A Ledermann Rebecca Asher Richard T Penson Amit M Oza Jacob Korach Tomasz Huzarski Sandro Pignata Michael Friedlander Alessandra Baldoni Tjoung-Won Park-Simon Kenji Tamura Gabe S Sonke Alla Lisyanskaya Jae-Hoon Kim Elias Abdo Filho Tsveta Milenkova Elizabeth S Lowe Phil Rowe Ignace Vergote Eric Pujade-Lauraine the SOLO/ENGOT-Ovinvestigators 王娟(校) 李征(校) | 2021 | 肿瘤药学2021，11，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员